Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Myelodysplastic Syndromes
•
Hematology
Would you hold off iron chelation in a transfusion dependent MDS patient with elevated ferritin but with negative iron stain on the bone marrow?
Are there other investigations you would pursue to guide decision?
Related Questions
How do you modify HMA treatments for a patient with high-risk MDS experiencing prolonged cytopenias after each cycle?
How do you approach imetelstat therapy in MDS patients with baseline neutropenia or thrombocytopenia?
How do you manage high-risk MDS IB2 patients on HMA and venetoclax who develop an acute stroke requiring antiplatelet therapy?
How do you sequence luspatercept and imetelstat for treatment of anemia in MDS?
What is your approach to management of relapsed/refractory T-cell prolymphocytic leukemia (T-PLL)?
How would you approach transfusion-dependent anemia in an intermediate-risk MDS patient refractory to azacitidine?
How does the CLL17 trial presented at ASH 2025 change current practice guidelines?
In light of data from TRIANGLE, ECHO, and ENRICH, what is the best strategy to treat newly diagnosed patients with the blastoid variant MCL?
What is your standard for monitoring triglyceride level during therapy for ALL, particularly in regards to receiving pegaspargase?
Can AMPLIFY data be extrapolated to use of other BTKi's in combination with venetoclax or would you only ever use acalabrutinib/venetoclax in first line?